Latest news with #LifeSciences
Yahoo
17 hours ago
- Business
- Yahoo
Mettler-Toledo price target raised to $1,260 from $1,200 at BofA
BofA raised the firm's price target on Mettler-Toledo (MTD) to $1,260 from $1,200 and keeps a Neutral rating on the shares. The firm is updating its price targets for stocks under its coverage in the Life Sciences & Diagnostic Tools, LSTs, sector, the analyst tells investors. The firm notes LSTs remain under pressure as uncertainty persists with the macro environment and U.S. government policies. Recent weeks, however, have seen some signs of improvement as tariff concerns have cools slightly, the firm adds. Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See today's best-performing stocks on TipRanks >> Read More on MTD: Disclaimer & DisclosureReport an Issue Mettler-Toledo initiated with an Overweight at Barclays Citi adds 'upside 90-day short-term view' on Mettler-Toledo MongoDB and Asana downgraded: Wall Street's top analyst calls UBS upgrades Mettler-Toledo to Buy into growth reacceleration UBS upgrades Mettler-Toledo to Buy ahead of growth reacceleration Fehler beim Abrufen der Daten Melden Sie sich an, um Ihr Portfolio aufzurufen. Fehler beim Abrufen der Daten Fehler beim Abrufen der Daten Fehler beim Abrufen der Daten Fehler beim Abrufen der Daten
Yahoo
17 hours ago
- Business
- Yahoo
Waters price target raised to $375 from $370 at BofA
BofA analyst Michael Ryskin raised the firm's price target on Waters (WAT) to $375 from $370 and keeps a Neutral rating on the shares. The firm is updating its price targets for stocks under its coverage in the Life Sciences & Diagnostic Tools, LSTs, sector, the analyst tells investors. The firm notes LSTs remain under pressure as uncertainty persists with the macro environment and U.S. government policies. Recent weeks, however, have seen some signs of improvement as tariff concerns have cools slightly, the firm adds. Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See Insiders' Hot Stocks on TipRanks >> Read More on WAT: Disclaimer & DisclosureReport an Issue Waters Corporation Amends Credit Agreement for Flexibility Waters Corporation Re-elects Board at Annual Meeting Waters Corporation's Strategic Acquisition of Halo Labs: Enhancing Biologics Capabilities and Market Position Waters acquires Halo Labs Waters price target raised to $370 from $350 at BofA Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 days ago
- Business
- Yahoo
Clarivate Secures Major Multi-Year Partnership with Canadian Universities
Clarivate (NYSE:CLVT) is one of the best mid cap growth stocks to invest in now. Earlier on June 3, Clarivate announced a multi-year partnership with the Canadian Research Knowledge Network/CRKN. The agreement grants 55 Canadian universities expanded access to Clarivate's Web of Science platform to foster inter-member research collaborations and enhance the accessibility of Web of Science content for all participating institutions. The Web of Science platform is renowned for its Web of Science Core Collection, which serves as the world's first and most trusted publisher-neutral citation index. The platform streamlines the discovery of diverse content, such as leading journals, conference papers, books, dissertations, theses, datasets, patents, preprints, awarded grants, and policy documents. A state-of-the-art computer lab filled with engineers working on new analytics technologies. Under the new agreement, CRKN members will gain extended access to the Web of Science API, which will enable researchers to use the rich metadata for their projects. Additionally, access to the Derwent Innovations Index and the Policy Citation Index will allow members to better understand the societal impact of their research outputs. Clarivate (NYSE:CLVT) is a global information services provider. It operates through 3 segments: Academia & Government, Life Sciences & Healthcare, and Intellectual Property. CRKN is a consortium that comprises libraries and research institutions across Canada. While we acknowledge the potential of CLVT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey.
Business Insider
21-06-2025
- Business
- Business Insider
180 Life Sciences files $500M mixed securities shelf
16:18 EDT 180 Life Sciences (ATNF) files $500M mixed securities shelf Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Yahoo
17-06-2025
- Business
- Yahoo
ZYUS Life Sciences Announces Closing of First Tranche of Unit Offering
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES SASKATOON, Saskatchewan, June 17, 2025--(BUSINESS WIRE)--ZYUS Life Sciences Corporation (the "Company") (TSXV: ZYUS), a Canadian-based life sciences company focused on the development and commercialization of novel cannabinoid-based pharmaceutical drug candidates for pain management, is pleased to announce that it has now completed a first tranche (the "First Tranche") of its non-brokered private placement (the "Offering") of up to 1,119,402 units of the Company (each a "Unit") for up to $750,000.00. Under the First Tranche of the Offering, 370,000 Units were issued at a price of $0.67 per Unit for gross proceeds of $247,900.00. Each Unit, priced at $0.67, consists of one common share of the Company (a "Common Share") and one-half of one Common Share purchase warrant (each whole Common Share purchase warrant, a "Warrant"), whereby each Warrant entitles the holder to acquire one Common Share at a price of $0.95 for a period of twenty-four months from the date of issuance, unless the term of the Warrant is accelerated pursuant to its terms (the "Acceleration Provision"). In accordance with the Acceleration Provision, if the volume-weighted average trading price of the Common Shares is greater than $3.00 for a period of 5 consecutive trading days on the TSX Venture Exchange (the "TSXV"), ZYUS will have the right to accelerate the expiry date of the Warrants. Proceeds of the Offering will be used for general corporate and working capital purposes. No finder's fees were paid in connection with the Offering. The Units were offered by way of private placement pursuant to exemptions from prospectus requirements under applicable securities laws. All securities issued under the First Tranche are subject to a hold period expiring October 17, 2025, in accordance with applicable securities laws and the policies of the TSXV. The Offering has received conditional approval from the TSXV and remains subject to final acceptance of the TSXV. The securities described herein have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act"), or any state securities laws, and may not be offered or sold within the United States or to, or for account or benefit of, U.S. persons except in compliance with the registration requirements of the U.S. Securities Act and applicable state securities laws or pursuant to available exemptions therefrom. This release does not constitute an offer to sell or a solicitation of an offer to buy of any securities in the United States. About ZYUS Life Sciences Corporation ZYUS (TSXV: ZYUS) is a life sciences company focused on the development and commercialization of novel cannabinoid-based pharmaceutical drug candidates for pain management. Through rigorous scientific exploration and clinical research, ZYUS aims to secure intellectual property protection, safeguarding its innovative therapies and bolstering shareholder value. ZYUS' unwavering commitment extends to obtaining regulatory approval of non-opioid-based pharmaceutical solutions, in pursuit of transformational impact on patients' lives. For additional information, visit or follow us on X @ZYUSCorp. Cautionary Note Regarding Forward-Looking Statements This news release contains "forward-looking information" within the meaning of applicable securities laws relating to the Company's business, the Company's ability to advance clinical research activities, obtain regulatory approval of cannabinoid-based pharmaceutical drug candidates and introduce products that act as alternatives to current pain management therapies such as opioids, receipt of TSXV final acceptance, closing the balance of the Offering and use of proceeds from the Private Placement. Any such forward-looking statements may be identified by words such as "expects", "anticipates", "intends", "contemplates", "believes", "projects", "plans", "will" and similar expressions. Readers are cautioned not to place undue reliance on forward-looking statements. Statements about, among other things, the Company's business, the Company's ability to advance clinical research activities, obtain regulatory approval of cannabinoid-based pharmaceutical drug candidates and introduce products that act as alternatives to current pain management therapies such as opioids, obtain TSXV final acceptance, closing the balance of the Offering and use of proceeds from the Private Placement are all forward-looking information. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management's reasonable assumptions, there can be no assurance that the Company will be able to achieve these results. The Company assumes no responsibility to update or revise forward-looking information to reflect new events or circumstances or actual results unless required by applicable law. Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this press release. View source version on Contacts ZYUS Media Inquiriesmedia@ 1-833-651-7723 ZYUS Investor Relationsinvestors@
